EC Number   |
Inhibitors |
Structure |
|---|
   2.7.1.171 | 1-deoxy-1-morpholin-4-yl-D-fructose |
- |
   |
| 2.7.1.171 | 1-deoxy-1-morpholin-4-yl-D-psicose |
- |
|
| 2.7.1.171 | 1-deoxy-1-morpholin-4-yl-D-ribulose |
- |
|
| 2.7.1.171 | 1-deoxy-1-morpholinofructose |
substrate and competitive inhibitor of fructosamine 3-kinase, doubles the rate of accumulation of glycated haemoglobin, but markedly decreases the amount of haemoglobin containing alkali-labile phosphate |
|
| 2.7.1.171 | 1-deoxy-1-morpholinofructose |
DMF, a selective FN3K inhibitor, inhibits CS-0777 phosphorylation in erythrocytes by about 20% |
|
| 2.7.1.171 | 3-O-methylsorbitol-lysine |
inhibitors based on sorbitol show competitive inhibition of the fructoseamine-3-kinase reaction but also prevent the formation of 3-deoxyglucosone, because there is no spontaneous decomposition of the product to 3-deoxyglucosone. For compounds blocked at C3, also there is no product formed. The Ki values of these compounds are approx. 0.5 mM. Although high for an in vivo drug, their apparent low toxicity make it possible to use them, at least in animals, to lower 3-deoxyglucosone levels |
|
| 2.7.1.171 | deoxymorpholinofructose |
a competitive inhibitor |
|
| 2.7.1.171 | more |
neither transferrin saturation nor ferritin are confounders for the FN3K activity |
|
| 2.7.1.171 | N6-D-psicosyl-L-lysine |
- |
|
